Wire · regulatory
Addressing China's Rise in Biotech by Removing Barriers: Q&A with John Stanford
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 August 2026 · Fusion42 review
China's biotech sector has significantly matured, shifting from imitative practices to genuine innovation, attracting a surge of global licensing deals. The US is considering tightening foreign investment screening to address potential national security risks while facing internal challenges in supply chain, clinical trials, and technology acquisition.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
The US is gearing up to restrict certain biotech deals with China, creating a tighter market for startups and investors navigating cross-border R&D partnerships. You need to reassess your foreign partnerships and capital sources now to avoid sudden regulatory roadblocks.
◆ Coverage
1 source · 4 Aug 2026
◆ Related on Wire
◆ Topics